Showing 8281-8290 of 9458 results for "".
- Endocannabinoids Effective in Lupus Modelhttps://practicaldermatology.com/news/endocannabinoids-effective-in-lupus-model/2457521/Zylö Therapeutics’ patented Nanopod™ aerogel delivery technology was used to demonstrate the efficacy of endocannabinoids in a model of cutaneous lupus in a study presented last month at the meeting of the American College of Rheumatology. There is growing evidence that t
- New AD Estimate: As Many As 16.5 Million Adults Have ADhttps://practicaldermatology.com/news/new-ad-estimate-as-many-as-165-million-adults-have-ad/2457524/As many as 16.5 million adults in America have atopic dermatitis (AD). This estimate comes from a new study from the Perelman School of Medicine at the University of Pennsylvania, which also projected 6.6 million of these adults have disease that wo
- Ortho Dermatologics' Altreno Now Available in the UShttps://practicaldermatology.com/news/ortho-dermatologics-altreno-now-available-in-the-us/2457526/Ortho Dermatologics launched Altreno (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. Altreno Lotion is the first and only tretinoin available in a lotion for acne. Altreno Lotion has been shown to be effective and generally well-tolerated
- Skin Cancer Foundation: Champions for Change Gala Raises $600,000https://practicaldermatology.com/news/skin-cancer-foundation-champions-for-change-gala-raises-600000/2457527/The Skin Cancer Foundation’s 22nd annual Gala raised $600,000 to support the organization’s educational campaigns, community programs, and research initiatives. More than 400 guests attended the event, including Skin Cancer Foundation donors, industry and physician allies, celebrity s
- Researchers Identify Genes Involved in Skin Cancerhttps://practicaldermatology.com/news/researchers-identify-genes-involved-in-skin-cancer/2457528/Researchers at the Health Sciences department of the Universitat Jaume I (UJI) of Castellón, Spain, have identified the genes responsible for sun sensitivity and skin cancer vulnerability. The Skin Cancer Genetics and Human Pigmentation research group (Melanogén) has analysed the sk
- Almirall, LLC is the New Name of Aquahttps://practicaldermatology.com/news/aqua-is-now-almirall/2457551/Almirall, LLC is the new name of Aqua Pharmaceuticals. Almirall, LLC is part of the larger Almirall, S.A. family, an internationally-recognized global dermatology pharmaceutical company, with a strong focus on skin health. The name change, was announced jointly by Almirall LLC Pre
- New from xMedica: Aesthetics Conference Features Energy Based Treatments for Male and Female Sexual Wellnesshttps://practicaldermatology.com/news/new-from-xmedica-aesthetics-conference-features-energy-based-treatments-for-male-and-female-sexual-wellness/2457553/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- Almirall's Seysara Set to Shake Up US Acne Markethttps://practicaldermatology.com/news/almiralls-seysara-set-to-shake-up-us-acne-market/2457557/The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older is set to shake up the currently stagnant acne market due to its ease of adminis
- Residents of Distinction Attend 2018 Coastal Dermatology Symposiumhttps://practicaldermatology.com/news/residents-of-distinction-attend-2018-coastal-dermatology-symposium/2457554/As part of the dermMentors Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 14th Annual Coastal Dermatology Symposium, held in Monterey, CA October 3-6, 2018. The 2018 dermMentors™
- Aclaris Acquires Rhofade from Allerganhttps://practicaldermatology.com/news/aclaris-acquires-rhofade-from-allergan/2457561/Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intel